Global Breast Cancer Monoclonal Antibodies Market is expected to reach 13.7 billion by 2020; Finds New Report

Report forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.

The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

According to the report, exposure to risk factors will be a key driver for market growth. Exposure to risk factors for breast cancer and the decrease in practices that reduce this risk are expected to increase the incidence of breast cancer. The disease is associated with modifiable risk factors such as physical inactivity, alcohol consumption, obesity, and weight gain. For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. Oral contraceptives and postmenopausal estrogen-progestogen hormone replacement therapy increase the risk of the developing the disease because they contain synthetic sex hormones. Overweight postmenopausal women have elevated estrogen levels because they have more estrogen-producing fatty tissue. These levels increase the likelihood of developing the disease. Physical activity helps lower estrogen levels, and thus negates the risk factors. Breastfeeding is also known to protect women against breast cancer.

Further, the report states that the number of patients available for clinical studies is less, making it difficult to generate significant comparative data. This is a major challenge in conducting clinical studies and for the market. The participation of sites across multiple geographies is required, but only very few patients are enrolled at each site. This may lead to delays in the recruitment process, which can add to the cost and uncertainty of the program. Pharmaceutical companies developing mAbs conduct clinical trials on a limited patient population. This requires efforts to mitigate the higher risk of uncertainty associated with the use of these drugs and accelerates approval procedures. The US FDA mandates manufacturers to satisfy Risk Evaluation and Mitigation Strategy (REMS) programs that include elements to ensure safe use before and after approval. The assessment of safety labels during clinical trials becomes difficult because of the limited availability of premarket data for the evaluation of mAbs and the smaller patient population.

Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the global breast cancer monoclonal antibodies (mAbs) market: Roche, Amgen, and Mylan.

Other Prominent Vendors in the market are: Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industriesf, Synta Pharmaceuticals, and Teva Pharmaceuticals.

Market driver

• Reimbursement benefits for breast cancer mAbs
• For a full, detailed list, view our report

Market challenge

• Absence of adequate diagnosis and screening procedures for early detection
• For a full, detailed list, view our report

Market trend

• Emergence of targeted and combination therapies for breast cancer
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 88 pages and 56 Exhibit “Global Breast Cancer Monoclonal Antibodies Market 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Breast cancer: Overview, Pipeline portfolio, Market segmentation by type of mAbs, Market segmentation by end-user, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://mrr.cm/3qJ

Related Reports;

Global Point-of-Care Coagulation Testing Market 2016-2020 - Visit at - http://mrr.cm/3q3

Global Fetal and Neonatal Care Equipment Market 2016-2020 - Visit at - http://mrr.cm/3qU

Global Capnography Market 2016-2020 - Visit at - http://mrr.cm/3qw

Global Vascular Guidewires Market 2016-2020 - Visit at - http://mrr.cm/3qi